Filtered By:
Source: Thrombosis Research
Condition: Thrombosis
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 219 results found since Jan 2013.
Neutrophil extracellular traps in thrombi retrieved during interventional treatment of ischemic arterial diseases
The ultrastructure and cellular composition of thrombi has a profound effect on the outcome of acute ischemic stroke (AIS), coronary (CAD) and peripheral artery disease (PAD). Activated neutrophils release a web-like structure composed mainly of DNA and citrullinated histones, called neutrophil extracellular traps (NET) that modify the stability and lysability of fibrin. Here, we investigated the NET-related structural features of thrombi retrieved from different arterial localizations and their interrelations with routinely available clinical data.
Source: Thrombosis Research - January 15, 2019 Category: Hematology Authors: Ádám Z. Farkas, Veronika J. Farkas, István Gubucz, László Szabó, Krisztián Bálint, Kiril Tenekedjiev, Anikó I. Nagy, Péter Sótonyi, László Hidi, Zoltán Nagy, István Szikora, Béla Merkely, Krasimir Kolev Tags: Full Length Article Source Type: research
Gut microbiota-dependent trimethylamine-N-oxide (TMAO) shows a U-shaped association with mortality but not with recurrent venous thromboembolism
Gut microbiota-dependent trimethylamine-N-oxide (TMAO) correlates with arterial thrombotic events including myocardial infarction and stroke, and mortality. However, the association of TMAO with recurrent venous thromboembolism (VTE) and mortality remains unknown.
Source: Thrombosis Research - December 7, 2018 Category: Hematology Authors: Martin F. Reiner, Daniel M üller, Sara Gobbato, Odile Stalder, Andreas Limacher, Nicole R. Bonetti, Lisa Pasterk, Marie Méan, Nicolas Rodondi, Drahomir Aujesky, Anne Angelillo-Scherrer, Christian M. Matter, Thomas F. Lüscher, Giovanni G. Camici, Arnold Tags: Full Length Article Source Type: research
Apixaban and rivaroxaban in patients with cerebral venous thrombosis
Cerebral venous thrombosis (CVT) affects approximately 15 people per million annually and represents 0.5% of all stroke [1,2]. Initiation of anticoagulation with heparin followed by warfarin is currently the standard of care, after confirmation of diagnosis with computed tomography (CT) or magnetic resonance (MR) venography [3]. Apixaban and rivaroxaban have been shown to be non-inferior to warfarin for the treatment of deep vein thrombosis and pulmonary embolism [4,5]. However, only case reports and small case series have described their use in patients with CVT.
Source: Thrombosis Research - November 20, 2018 Category: Hematology Authors: Fahrettin Covut, Tariq Kewan, Oscar Perez, Monica Flores, Abdo Haddad, Hamed Daw Tags: Letter to the Editors-in-Chief Source Type: research
Ninety-day prognosis of patients receiving direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: The real life evidence
Patients who receive antithrombotic therapy as secondary prevention in the early phase of non valvular atrial fibrillation (NVAF)-related acute ischemic stroke (AIS) have a better prognosis compared with patients who do not receive antithrombotic treatment [1]. In the VISTA registry the incidence of stroke recurrence, symptomatic intracranial bleeding, all-cause mortality and 90-day modified Rankin Scale (mRS) ≥4 in patients with NVAF-related AIS not receiving antithrombotic treatment was 19.8%, 9.3%, 40.7% and 65.3%, respectively compared with patients receiving vitamin K antagonists (VKAs) (10.6%, 2.9%, 25.5% and 46.6%...
Source: Thrombosis Research - November 3, 2018 Category: Hematology Authors: Luca Masotti, Elisa Grifoni, Alessandro Dei, Vieri Vannucchi, Federico Moroni, Stefano Spolveri, Grazia Panigada, Giancarlo Landini Tags: Letter to the Editors-in-Chief Source Type: research
9. Abstract Title: Measurement of anti-factor Xa direct oral anticoagulant levels in the plasma samples from the perioperative anticoagulant use for surgery evaluation (PAUSE) study
We report a new assay that measures anti-FXa DOAC levels in plasma and whole blood. This is achieved by measuring the rate of prothrombin cleavage by residual FXa activity, which is inversely proportional to the DOAC levels present.
Source: Thrombosis Research - October 1, 2018 Category: Hematology Authors: Luca R. Di Giuseppantonio, Chengliang Wu, Peter L. Gross, James D. Douketis, Paul Y. Kim Source Type: research
6. Abstract Title: Thrombotic and Bleeding Outcomes Following Perioperative Interruption of DOACs and VKAs in Patients with Non-Valvular Atrial Fibrillation - A Comparative Analysis
Background: Atrial fibrillation (AF) is a common disorder that will affect up to 5.6 million patients in the U.S. by 2050. Both direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs), typically warfarin, are used for stroke prevention in AF and such patients frequently undergo invasive procedures, requiring anticoagulant interruption. Temporary interruption of anticoagulants can be associated with significant morbidity and mortality in the form of thromboembolic and bleeding complications.
Source: Thrombosis Research - October 1, 2018 Category: Hematology Authors: Joseph Shaw, Tinghua Zhang, Gregoire Le Gal, James Douketis, Marc Carrier Source Type: research
1. Abstract Title: Management of Cerebral Vein Thrombosis in a Large Canadian Tertiary Hospital
Introduction: Cerebral vein thrombosis (CVT) is an uncommon cause of stroke and is more likely to affect young adults and children. Women have a three-fold increased risk compared to men, owing to gender specific factors such as oral contraceptive use (OCP), pregnancy, and hormone replacement therapies. The presenting symptoms of CVT are non-specific and include headache, seizure, focal neurological deficits, or coma as the most severe presentation. The rarity and variable symptoms of the disease leads to delayed diagnosis and implementation of treatment.
Source: Thrombosis Research - October 1, 2018 Category: Hematology Authors: Lana Castellucci, Philip Chiang Source Type: research
The effect of tyramine infusion and exercise on blood flow, coagulation and clot microstructure in healthy individuals
In this study we explore the relationship between catecholamine release and hemodynamic changes and their effect on coagulation.
Source: Thrombosis Research - July 26, 2018 Category: Hematology Authors: Matthew J. Lawrence, Gareth Davies, Michael Nyberg, Janet Whitley, Vanessa Evans, Rhodri Williams, Ylva Hellsten, Phillip A. Evans Tags: Full Length Article Source Type: research
Appropriateness of non-vitamin K antagonist oral anticoagulant dose in patients with atrial fibrillation in Israel: A population-based study
The non-vitamin K oral antagonists (NOACs) are at least as effective as warfarin in the prevention of stroke in non valvular atrial fibrillation (NVAF) and are associated with less intracranial hemorrhage. Many patients with NVAF inappropriately do not receive anticoagulants often because of the inconvenience associated with warfarin administration. NOACs have the potential to increase anticoagulation use because they are safer and easier to administer than warfarin. Indeed, the use of anticoagulation in patients with newly diagnosed AF in many countries is increasing as a result of the use of NOACs in preference to warfarin [1].
Source: Thrombosis Research - July 24, 2018 Category: Hematology Authors: Martin H. Ellis, Sari Greenberg Dotan, Ariel Hammerman, Erez Battat, Estela Derazne, Orly Avnery Tags: Letter to the Editors-in-Chief Source Type: research
Treatment of arterial thrombosis in children: Methods and mechanisms
Arterial thrombosis is increasingly recognized in children and is mostly related to the presence of an arterial catheter or an ischemic stroke. Treatment of children with arterial thrombosis varies widely and consists on the administration of the common available anticoagulant und antiplatelet drugs. No evidence-based guidelines are available so far to prefer one treatment approach to another. Data in adults indicate that understanding the pathomechanism and composition of arterial thrombosis is crucial for choosing the most efficient and safe antithrombotic drug.
Source: Thrombosis Research - July 6, 2018 Category: Hematology Authors: Mattia Rizzi, Manuela Albisetti Tags: Review Article Source Type: research
Sub therapeutic rivaroxaban plasma concentrations following administration via Percutaneous Endoscopic Gastrostomy (PEG) feeding tubes – A note of caution
Rivaroxaban is a direct factor Xa inhibitor currently licensed for the acute treatment and prevention of venous thromboembolism and for the prevention of stroke in the context of atrial fibrillation (AF). Rivaroxaban is rapidly absorbed with maximum concentrations reported around 2 –4 h post ingestion. Oral bioavailability is high (80–100%) for the 2.5 mg and 10 mg tablet dose under fasting conditions or with food. The 20 mg dose of rivaroxaban has reduced bioavailability of 66%, under fasting conditions, increasing to near 100% when taken with food [1, 6].
Source: Thrombosis Research - June 19, 2018 Category: Hematology Authors: Rosalind Byrne, Alison Brown, Jignesh P. Patel, Julia Czuprynska, Lara N. Roberts, Raj K. Patel, Roopen Arya Tags: Letter to the Editors-in-Chief Source Type: research
Prothrombotic mechanisms in patients with congenital p.Cys89Tyr mutation in CD59
Nonfunctioning CD59 is a major risk factor for stroke and hypercoagulability. Uncontrolled hemolysis causes massive MP release and endothelial heme damage. MAC attack on unprotected endothelium and platelet activation and aggregation with leukocytes mediate additional mechanisms leading to vascular occlusion. It is suggested that CD59 loss represents a major arterial prothrombotic factor in PNH and additional diseases.
Source: Thrombosis Research - June 11, 2018 Category: Hematology Authors: Adi Tabib, Issam Hindi, Netanel Karbian, Orly Zelig, Batla Falach, Dror Mevorach Tags: Full Length Article Source Type: research
Can an anticoagulant reduce brain hemorrhage: Invited comment on “Dabigatran reduces endothelial permeability through inhibition of thrombin-induced cytoskeleton reorganization”
During studies of anti-coagulants to prevent cardioembolic stroke, startling data emerged that patients treated with novel oral anti-coagulants (NOACs) appeared to suffer less brain hemorrhage than patients treated with traditional, vitamin-K depleting anticoagulants [1, 2]. That NOACs reduced the bleeding risk did not fit accepted dogma: clinicians imagine that hemorrhage occurs during and following ischemic stroke as the brain undergoes necrosis. In the presence of anti-coagulation, such necrotic bleeding ought to be augmented.
Source: Thrombosis Research - June 11, 2018 Category: Hematology Authors: Patrick D. Lyden Tags: Editorial Source Type: research
Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation
New oral anticoagulants are non-inferior compared with warfarin regarding stroke prevention in atrial fibrillation, with similar or decreased risk of bleeding. However, it is unclear whether high TTR warfarin is as effective and safe as NOACs. Our objective was to investigate efficacy and safety of apixaban, dabigatran or rivaroxaban compared with warfarin in clinical practice.
Source: Thrombosis Research - May 17, 2018 Category: Hematology Authors: Sara Sj älander, Vilhelm Sjögren, Henrik Renlund, Bo Norrving, Anders Själander Tags: Full Length Article Source Type: research
Dabigatran reduces endothelial permeability through inhibition of thrombin-induced cytoskeleton reorganization
Dabigatran etexilate (DE), a new oral anti-coagulant, is a direct thrombin inhibitor. Clinical trials showed the favorable benefit-to-risk profile of DE compared to warfarin for the prevention of ischemic stroke in patients with atrial fibrillation. Remarkably, patients treated with dabigatran showed reduced rates of intracerebral hemorrhage compared to warfarin. As the breakdown of endothelial barrier integrity is associated with hemorrhagic events and as thrombin increases endothelial permeability, we hypothesized that dabigatran preserves the endothelial barrier by inhibiting thrombin-induced permeability.
Source: Thrombosis Research - April 25, 2018 Category: Hematology Authors: Hyun-Jung Choi, Na-Eun Kim, Jayoung Kim, Sunho An, Seung-Hee Yang, Jimin Ha, Sunghee Cho, Il Kwon, Young Dae Kim, Hyo Suk Nam, Ji Hoe Heo Tags: Full Length Article Source Type: research
